Alessio Amatu
Alessio Amatu
Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
Zweryfikowany adres z ospedaleniguarda.it
Cytowane przez
Cytowane przez
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ...
Nature medicine 21 (7), 795-801, 2015
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1 …
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
A Amatu, A Sartore-Bianchi, S Siena
ESMO open 1 (2), e000023, 2016
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
Adaptive mutability of colorectal cancers in response to targeted therapies
M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ...
Science 366 (6472), 1473-1480, 2019
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
Journal of the National Cancer Institute 109 (12), djx089, 2017
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ...
Gut 67 (11), 1995-2005, 2018
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
A Amatu, A Sartore-Bianchi, K Bencardino, EG Pizzutilo, F Tosi, S Siena
Annals of Oncology 30, viii5-viii15, 2019
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer
A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ...
JNCI: Journal of the National Cancer Institute 108 (1), 2016
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer …
A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomatà, V Fiano, ...
Annals of oncology 26 (9), 1994-1999, 2015
Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis
F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ...
Clinical colorectal cancer 16 (3), e153-e163, 2017
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer
G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ...
Cancer Cell 34 (1), 148-162. e7, 2018
Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal CancerMGMT as a …
A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ...
Clinical cancer research 19 (8), 2265-2272, 2013
HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer
A Sartore‐Bianchi, A Amatu, L Porcu, S Ghezzi, S Lonardi, F Leone, ...
The oncologist 24 (10), 1395-1402, 2019
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma
G Poggi, A Amatu, B Montagna, P Quaretti, C Minoia, C Sottani, L Villani, ...
Cardiovascular and interventional radiology 32, 1187-1192, 2009
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20